By detecting tumor immune environments at different stages, PD-1, an immune checkpoint inhibitor, was combined with better immune environment on the 5th day after PTT to achieve excellent efficacy in the treatment of primary or distal tumor and metastasis. Here, PDCD1 is linked to neoplasm.